Lupin Limited (LUPIN.NS)
Makes generic and branded medicines for diseases like diabetes, heart conditions, and infections
2,447.00+0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+31.0%
The outlook
Lupin trades at 2447, sitting near the upper end of its 52-week range and above both its 50- and 200-day moving averages. Analyst consensus leans toward "Buy" with an average target about 2% above the current price. The stock carries a trailing P/E of 21.0 and shows a bullish lean in overall sentiment.
What’s behind the score
Analyst consensusBuy — 2.5 avg of 37 analysts
Price trendAbove its 50- & 200-day averages
52-week range88% of the way from its 52-week low to high
Price targetAvg target +2% vs current price
Analyst price target
~12-month · 37 analysts2,488.68average target+1.7% vs now
Now 2,447.00
Low 1,800.00High 3,095.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.12T
52-wk high
2,529.50
52-wk low
1,836.80
50-day avg
2,360.33
200-day avg
2,230.87
Trailing P/E
21.0